Alliance Global adjusted the firm’s price target on Intensity Therapeutics (INTS) to $30 from $3.50 and keeps a Buy rating on the shares following Intensity’s 1-for-25 reverse stock split on February 13. The firm values INT230-6 for TNBC at $20 per share, INT230-6 for STS at $1 per share, INT230-6 for TNBC at $6.50 per share, and the remaining compounds and cash at $3.50 per share, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics provides update on INVINCIBLE-4 Study
- Intensity Therapeutics, Inc. (INTS) Q4 Earnings Cheat Sheet
- Intensity Therapeutics Regains Nasdaq Compliance, Stabilizing Market Listing
- Intensity Therapeutics regains Nasdaq compliance
- Intensity Therapeutics Inc trading halted, news pending